2025-02-24
The ATMP Center at Skåne University Hospital in Lund is joining a European initiative to improve the efficiency and sustainability of manufacturing processes for cell and gene therapies.
The ATMP Center at Skåne University Hospital in Lund is joining a European initiative to improve cell and gene therapy production. The RHYTHMS project aims to advance next-generation therapies and meet the rising demand for sustainable ATMP manufacturing. A European consortium is leading the initiative, with support from the EU’s Eurostars program. This program is the largest international funding initiative for SMEs developing innovative products, processes, or services. The three-year project is led by the Dutch company Scinus Cell Expansion.
In early 2025, the ATMP Center will open a state-of-the-art facility for producing cell and gene therapies. These treatments target diseases previously considered untreatable.
“We will manufacture advanced medicinal products using pluripotent stem cells, following Good Manufacturing Practice (GMP) regulations,” says Gisela Helenius, Head of the ATMP Center at Skåne University Hospital. “The project will optimize production by monitoring nutrient levels in real time during different growth phases. Our role is to test bioreactor performance in GMP manufacturing. Through our collaboration with Lund University, a leader in pluripotent stem cell research, we will strengthen expertise in this field.”
The ATMP Center is a key contact point for industry, academia, and clinical investigators. It provides guidance and support for integrating ATMPs into clinical trials. Since these trials have strict regulatory requirements, early engagement with the center helps avoid delays.